(firstQuint)A Study of LY2875358 in Japanese Participants With Advanced Cancer.

 This study has 3 parts.

 Participants may only enroll in one part.

 Part A - Participants will receive LY2875358.

 Part B1 - Participants with non-small cell lung cancer (NSCLC) will receive LY2875358 and erlotinib.

 Part B2 - Participants with NSCLC will receive LY2875358 and gefitinib.

 Parts B1 and B2 were added per protocol amendment in January, 2013.

.

 A Study of LY2875358 in Japanese Participants With Advanced Cancer@highlight

The purpose of this study is to assess the safety and tolerability of LY2875358 in Japanese participants with cancer that is advanced and/or may have spread to another part of the body.

